Warning Letter — TSP Solutions Pte. Ltd.
The FDA's Center for Drug Evaluation and Research issued a Warning Letter to TSP Solutions Pte. Ltd. on October 22, 2026. The source indicates this action follows regulatory review but does not detail specific cGMP violations in the provided excerpt.
This affects TSP Solutions Pte. Ltd. and personnel responsible for quality oversight, regulatory submissions, and pharmaceutical manufacturing operations at their facilities.
The issuance of a Warning Letter from CDER signifies that the FDA has identified significant violations of regulatory requirements. While the specific nature of the deficiencies is not detailed in the excerpt, such letters typically result in increased regulatory scrutiny, potential withholding of product approvals, and requirements for rigorous corrective actions. Regulatory teams should view this as a signal of enforcement priority regarding the company's compliance status.
Conduct a comprehensive review of manufacturing site registrations and quality management systems to ensure compliance with CDER requirements. Verify that all facility information provided to the FDA is current and accurate to avoid enforcement actions.
FDA Warning Letter issued to: TSP Solutions Pte. Ltd.. 10/22/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tsp-solutions-pte-ltd-735071-10222026
Open in openFDA / FDA.gov